US HB6710 | 2021-2022 | 117th Congress

Status

Spectrum: Partisan Bill (Republican 21-0)
Status: Introduced on February 11 2022 - 25% progression, died in committee
Action: 2022-02-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.

Sponsors


History

DateChamberAction
2022-02-14HouseReferred to the Subcommittee on Health.
2022-02-11HouseReferred to the House Committee on Energy and Commerce.
2022-02-11HouseIntroduced in House

Same As/Similar To

HB4792 (Related) 2021-09-03 - Referred to the Subcommittee on Energy and Mineral Resources.

Subjects


US Congress State Sources


Bill Comments

feedback